Characteristics and diagnosis and treatment progress of nonalcoholic steatohepatitis-related hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-2015.2020.06.007

Abstract

Abstract:

Considering that nonalcoholic fatty liver disease(NAFLD)has become the world′s first chronic liver disease, patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma(NASH-HCC)have increased dramatically, and it has leapt to the most common cause of liver cancer.Unlike other causes of liver cancer, NASH-HCC is strongly associated with the cluster of risk factors including genetic factors, metabolic syndrome, gut microbiota and chronic persistent inflammation.Clinically, NASH-HCC mostly occurs in aging, male, obese patients, and can evolve from NAFLD without cirrhosis.The relatively characteristic manifestations of NASH-HCC in ultrasound, CT and MRI examinations are significantly different from other causes of liver cancer.This article reviews the characteristics and the progress of NASH-HCC in diagnosis and treatment.

Key words: Nonalcoholic fatty liver disease, Hepatocellular carcinoma, Nonalcoholic steatohepatitis-related hepatocellular carcinoma

Li Chen, Fengshang Zhu, Changqing Yang. Characteristics and diagnosis and treatment progress of nonalcoholic steatohepatitis-related hepatocellular carcinoma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2020, 10(06): 267-271.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2020.06.007

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2020/V10/I06/267

References 36

1	Anstee QM, Reeves HL, Kotsiliti E，et al.From NASH to HCC：current concepts and future challenges [J]．Nat Rev Gastroenterol Hepatol，2019,16(7):411-428.
2	Argyrou C, Moris D, Vernadakis S．Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis，prevention and treatment [J]．J BUON，2017,22(1):6-20.
3	Eslam M, Newsome PN, Sarin SK，et al.A new definition for metabolic dysfunction-associated fatty liver disease：An international expert consensus statement [J]．J Hepatol，2020,73(1):202-209.
4	Degasperi E, Colombo M．Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease [J]．Lancet Gastroenterol Hepatol，2016,1(2):156-164.
5	Umano GR, Caprio S, Di Sessa A，et al.The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth [J]．Am J Gastroenterol，2018,113(3):376-383.
6	Donati B, Dongiovanni P, Romeo S，et al.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals[J]．Sci Rep，2017,7(1):4492.
7	Sutti S, Albano E．Adaptive immunity：an emerging player in the progression of NAFLD [J]．Nat Rev Gastroenterol Hepatol，2020,17(2):81-92.
8	Wu WKK, Zhang L, Chan MTV.Autophagy，NAFLD and NAFLD-Related HCC [J]．Adv Exp Med Biol，2018,1061:127-138.
9	Borrelli A, Bonelli P, Tuccillo FM，et al.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma：Current and innovative therapeutic approaches [J]．Redox Biol，2018,15:467-479.
10	Chow MD, Lee YH, Guo GL.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]．Mol Aspects Med，2017,56:34-44.
11	Pennisi G, Celsa C, Giammanco A，et al.The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease：Screening Issue and Future Perspectives [J]．Int J Mol Sci，2019,20(22):5613.
12	Hashimoto E, Yatsuji S, Tobari M，et al.Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis [J]．J Gastroenterol，2009,44 Suppl 19:89-95.
13	Kawamura Y, Arase Y, Ikeda K，et al.Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma[J]．Am J Gastroenterol，2012,107(2):253-261.
14	Golabi P, Rhea L, Henry L, Younossi ZM.Hepatocellular carcinoma and non-alcoholic fatty liver disease [J]．Hepatol Int，2019,13(6):688-694.
15	Than NN, Ghazanfar A, Hodson J，et al.Comparing clinical presentations，treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease [J]．QJM，2017,110(2):73-81.
16	Tan H, Xu L, Liu X，et al.Hepatocellular carcinoma in nonalcoholic fatty liver disease mimicking benign hemangioma：two case reports and literature review [J]．Int J Clin Exp Pathol，2015,8(11):15350-15355.
17	Al-Sharhan F, Dohan A, Barat M，et al.MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis(NASH)[J]．Eur J Radiol，2019,119:108648.
18	Garcovich M, Faccia M, Meloni F，et al.Contrast-enhanced ultrasound patterns of hepatocellular adenoma：an Italian multicenter experience [J]．J Ultrasound，2019,22(2):157-165.
19	Hwang A, Shi C, Zhu E，et al.Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis；An OAD to NASH[J]．PLoS One，2018,13(6):e0198937.
20	Montagnana M, Danese E, Lippi G．Squamous cell carcinoma antigen in hepatocellular carcinoma：Ready for the prime time [J]? Clin Chim Acta，2015,445:161-166.
21	Gori M, Arciello M, Balsano C．MicroRNAs in nonalcoholic fatty liver disease：novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma[J]．Biomed Res Int，2014:741465.
22	Ye J, Li T S, Xu G，et al.JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity [J]．Cancer Res，2017,77(19):5287-5300.
23	Nakamura N, Hatano E, Iguchi K，et al.Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease：from pig model to human study [J]．BMC Cancer，2019,19(1):621.
24	Best J, Bechmann L P, Sowa J P，et al.GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]．Clin Gastroenterol Hepatol，2020,18(3):728-735.
25	朱风尚，杨长青，陈锡美．非酒精性脂肪性肝炎肝纤维化血清学无创诊断[J/CD]．中华消化病与影像杂志(电子版)，2014,3(6):38-41.
26	Yoneda M, Imajo K, Eguchi Y，et al.Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels [J]．J Gastroenterol，2013,48(9):1051-1060.
27	Hsu C Y, Lee Y H, Liu P H，et al.Decrypting cryptogenic hepatocellular carcinoma：clinical manifestations，prognostic factors and long-term survival by propensity score model [J]．PLoS One，2014,9(2):e89373.
28	Lim C, Bhangui P, Salloum C，et al.Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma [J]．J Hepatol，2018,68(1):100-108.
29	寇昌华，韩锡林，庄惠杰，等．脂肪肝合并肝癌患者接受根治术后的临床疗效与安全性分析[J]．中国现代医生，2017,55(30):8-10.
30	Koh Y X, Tan H J, Liew Y X，et al.Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma [J]．J Am Coll Surg，2019,229(5):467-478.
31	刘晓燕，李胜棉，杨俭.1293例原发性肝癌患者非酒精性脂肪性肝病的伴发率及预后特征[J]．临床肝胆病杂志，2010,26(6):641-643.
32	Xu W, Zhang X, Wu J L，et al.O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress[J]．J Hepatol，2017,67(2):310-320.
33	Okada H, Takabatake R, Honda M，et al.Peretinoin，an acyclic retinoid，suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet [J]．Oncotarget，2017,8(25):39978-39993.
34	Bruix J, Qin S, Merle P，et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE)：a randomised，double-blind，placebo-controlled，phase 3 trial[J]．Lancet，2017,389(10064):56-66.
35	Abou-Alfa GK, Meyer T, Cheng AL，et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J]．N Engl J Med，2018,379(1):54-63.
36	El-Khoueiry A B, Sangro B, Yau T，et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040)：an open-label，non-comparative，phase 1/2 dose escalation and expansion trial [J]．Lancet，2017,389(10088):2492-2502.

[1]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[2]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[3]	Jie Dong, Song Yang, Hao Yang, Xiang Chen, Wanli Zhang. Relationship between hypermethylation of ACACB gene and clinicopathological factors and survival of hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 433-437.
[4]	Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.
[5]	Rongchang Wang, Qifeng Ou, Jinjie Huang, Caiqin Wang, Qian Wang, Xiaohui Huang. Expression of miR-145-5p in hepatocellular carcinoma and its clinical significance [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 197-202.
[6]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[7]	Mingxiu Ma, Feng Xu, Kailing Xie, Yaming Guo, Tonghui Lu, Chaoliu Dai. Preoperative alkaline phosphatase to prealbumin ratio predicting the prognosis of hepatocellular carcinoma after hepatectomy [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 99-103.
[8]	Hongxiang Yin, Jiakang Duan, Bowen Jiang, Yi Tan. Predictive value of combined systemic immunoinflammatory index and prognostic nutritional index on the prognosis of patients with hepatocellular carcinoma after radical resection [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 93-98.
[9]	Qijian Yu, Zhe Yang, Shusen Zheng. Current status and progress of research on prevention of tumor recurrence after liver transplantation for hepatocellular carcinoma [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 171-179.
[10]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[11]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[12]	Fengyun Wu, Xin Teng, Lianjuan Liu. Diagnostic value of high-frequency ultrasonography and enhanced magnetic resonance for primary hyperdifferentiated hepatocellular carcinoma of different diameters [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 404-408.
[13]	Zhongbai Liu, Yongjun Ren. Current status and progress of interventional therapy for hepatocellular carcinoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 111-115.
[14]	Xueqing Huang, Nan Wei, Tianpeng Jiang, Tianzhi An, Min Xu, Shi Zhou. Clinical study of TACE for hepatocellular carcinoma by ultrasound-guided transdistal radial artery approach [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(03): 251-256.
[15]	Yawei He, Wanjing Chen, Jiahong Song, Gang Yu, Benli Jia, Yong Wang. Study on the relationship between SCH, serum vitamin D levels and the severity of NAFLD in patients with obesity [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(02): 95-101.

Please choose a citation manager

Content to export